US2008008662A1PendingUtilityA1

Aerosol Drug Inhibition of Lung Cancer

64
Individually held — no corporate assignee on recordPriority: May 20, 2002Filed: Sep 21, 2007Published: Jan 10, 2008
Est. expiryMay 20, 2022(expired)· nominal 20-yr term from priority
Inventors:J. Vernon KnightJ. Clifford WaldrepNadezhda Koshkina
A61K 9/127A61K 31/7048A61K 31/704A61K 31/337A61K 9/0078A61K 31/4745A61P 11/00A61K 38/13
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.

Claims

exact text as granted — not AI-modified
1 . A method of inhibiting growth of a lung cancer in an individual comprising the steps of: 
 administering a dose of a lipid-drug enhancer liposomal complex; and, in sequence,    administering a dose of a lipid-anticancer drug liposomal complex, both of said liposomal complexes delivered via aerosolization from a nebulizer; whereby said drug enhancer and said anticancer drug inhibit growth of the lung cancer in the individual.    
   
   
       2 . The method of  claim 1 , wherein the sequential administration of said liposomal complexes is repeated at least once.  
   
   
       3 . The method of  claim 1 , wherein said drug enhancer is cyclosporin A, cyclosporin D, verapamil, ketoconazole, PCS 833, erythromycin, nifedipine, rapamycin or mibefradil.  
   
   
       4 . The method of  claim 1 , wherein said anti-cancer drug is paclitaxel, doxorubicin, etoposide, vinblastine, camptothecins, cisplatinum, carboplatinum, daunorubicin, or adriamycin.  
   
   
       5 . The method of  claim 1 , wherein said lipid has a transition temperature of about 17° C. or less.  
   
   
       6 . The method of  claim 1 , wherein said lipid is dilauroylphosphatidylcholine (DLPC).  
   
   
       7 . The method of  claim 1 , wherein said aerosol comprises about 5% to about 10% carbon dioxide.  
   
   
       8 . The method of  claim 1 , wherein said dose of said lipid-drug enhancer complex is a dose of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex.  
   
   
       9 . The method of  claim 8 , wherein said dose of dilauroylphosphatidylcholine-cyclosporin A liposomal complex comprises a concentration of cyclosporin A of about 5.0 mg cyclosporin A/ml solution in the nebulizer at a cyclosporin A:dilauroylphosphatidylcholine weight ratio of about 1:7.5.  
   
   
       10 . The method of  claim 1 , wherein said dose of a lipid-anticancer drug liposomal complex is a dose of a dilauroyl phosphatidylcholine-paclitaxel liposomal complex.  
   
   
       11 . The method of  claim 10 , wherein said dose of said dilauroylphosphatidylcholine-paclitaxel liposomal complex comprises a concentration of paclitaxel of about 10.0 mg paclitaxel/ml solution in the nebulizer at a paclitaxel: dilauroylphosphatidylcholine weight ratio of about 1:10.  
   
   
       12 . The method of  claim 1 , further comprising the step of: 
 concurrently administering a continuing dose of said lipid-drug enhancer liposomal complex with said lipid-anticancer drug complex via aerosolization from a nebulizer, wherein said lipid-drug enhancer liposomal complex is mixed with said lipid-anticancer drug complex in the nebulizer.    
   
   
       13 . The method of  claim 12 , wherein said dose of lipid-drug enhancer complex is a dose of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex.  
   
   
       14 . The method of  claim 13 , wherein said dose of dilauroylphosphatidylcholine-cyclosporin A liposomal complex comprises a concentration of cyclosporin A of about 5.0 mg paclitaxel/ml solution at a cyclosporin A: dilauroylphosphatidylcholine weight ratio of about 1:7.5 prior to mixing in the nebulizer.  
   
   
       15 . The method of  claim 12 , wherein said dose of lipid-anticancer drug complex is a dose of a dilauroylphosphatidylcholine-paclitaxel liposomal complex.  
   
   
       16 . The method of  claim 15 , wherein said dose of dilauroylphosphatidylcholine-paclitaxel liposomal complex comprises a concentration of paclitaxel of about 10.0 mg paclitaxel/ml solution at a paclitaxel: dilauroylphosphatidylcholine weight ratio of about 1:10 prior to mixing in the nebulizer.  
   
   
       17 . A method of inhibiting growth of a lung cancer in an individual comprising the steps of: 
 administering a dose of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex; and, in sequence,    administering a dose of a dilauroylphosphatidylcholine-paclitaxel liposomal complex, both of said liposomal complexes delivered via aerosolization from a nebulizer; whereby said cyclosporin A and said paclitaxel inhibit growth of the lung cancer in the individual.    
   
   
       18 . The method of  claim 17 , wherein the sequential administration of said liposomal complexes is repeated at least once.  
   
   
       19 . The method of  claim 17 , wherein said dose of dilauroylphosphatidylcholine-cyclosporin A liposomal complex comprises a concentration of cyclosporin A of about 5.0 mg cyclosporin A/ml solution in the nebulizer at a cyclosporin A:dilauroylphosphatidylcholine weight ratio of about 1:7.5.  
   
   
       20 . The method of  claim 17 , wherein said dose of dilauroylphosphatidylcholine-paclitaxel liposomal complex comprises a concentration of paclitaxel of about 10.0 mg paclitaxel/ml solution in the nebulizer at a paclitaxel:dilauroylphosphatidylcholine weight ratio of about 1:10.  
   
   
       21 . The method of  claim 17 , wherein said aerosol comprises about 5% to about 10% carbon dioxide.  
   
   
       22 . A method of inhibiting growth of a lung cancer in an individual comprising the steps of: 
 administering a dose of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex via aerosolization from a nebulizer; and, in sequence, administering a dose of a dilauroylphosphatidylcholine-paclitaxel liposomal complex while concurrently administering a continuing dose of said dilauroylphosphatidylcholine-cyclosporin A liposomal complex via aerosolization from a nebulizer wherein said dilauroylphosphatidylcholine-cyclosporin A liposomal complex is mixed with said dilauroylphosphatidylcholine-paclitaxel liposomal complex in the nebulizer,    whereby said cyclosporin A and said paclitaxel inhibit growth of the lung cancer in the individual.    
   
   
       23 . The method of  claim 22 , wherein the sequential and concurrent administration of said liposomal complexes is repeated at least once.  
   
   
       24 . The method of  claim 22 , wherein said dose of dilauroylphosphatidylcholine-cyclosporin A liposomal complex comprises a concentration of cyclosporin A of about 5.0 mg cyclosporin A/ml solution at a cyclosporin A:dilauroylphosphatidylcholine weight ratio of about 1:7.5 in the nebulizer for both the first administration of the dilauroylphosphatidylcholine-cyclosporin A liposomal complex and prior to mixing in the nebulizer for the continuing administration with said dilauroylphosphatidylcholine-paclitaxel liposomal complex.  
   
   
       25 . The method of  claim 22 , wherein said dose of dilauroylphosphatidylcholine-paclitaxel liposomal complex comprises a concentration of paclitaxel of about 10.0 mg paclitaxel/ml solution at a paclitaxel: dilauroylphosphatidylcholine weight ratio of about 1:10 prior to mixing in the nebulizer for the continuing administration with said dilauroylphosphatidylcholine-cyclosporin A liposomal complex.  
   
   
       26 . (canceled)

Join the waitlist — get patent alerts

Track US2008008662A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.